Skip to main content

Bio-Techne Corp Value Stock - Dividend - Research Selection

Bio-techne

ISIN: US09073M1045 , WKN: A12ENG

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Bio-Techne Stock: Is Wall Street Bullish or Bearish?

2025-11-14
Despite underperforming the broader market and biotechnology industry over the past year, analysts remain strongly bullish on Bio-Techne’s longer-term prospects.

Is Bio-Techne Corporation (TECH) a High-Quality Growth-Oriented Compounder Within The Healthcare Sector?

2025-11-13
ClearBridge Investments, an investment management company, released its “ClearBridge Mid Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In an environment of shifting monetary policy, stabilizing earnings, and improved sentiment, midcaps experienced growth in the third quarter. The Federal Reserve’s decision to cut rates helped small and mid-cap stocks […]

Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025

2025-11-12
Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025 Q3 revenues increased by 18% to $27.4 millionAdjusted EBITDA profitability of $1.0 million for Q3Acquisition of ExoDx business from Bio-Techne CorporationConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA – November 12, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for th

We Think You Can Look Beyond Bio-Techne's (NASDAQ:TECH) Lackluster Earnings

2025-11-12
The most recent earnings report from Bio-Techne Corporation ( NASDAQ:TECH ) was disappointing for shareholders. Despite...

Bio-Techne, Tandem Diabetes, Align Technology, DexCom, and Teleflex Shares Skyrocket, What You Need To Know

2025-11-11
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Bio-Techne Corporation (TECH) Presents at Stifel 2025 Healthcare Conference Transcript

2025-11-11
Bio-Techne Corporation (TECH) Stifel 2025 Healthcare Conference November 11, 2025 9:20 AM ESTCompany ParticipantsKim Kelderman - CEO, President &...

Bio-Techne Corporation (TECH) Presents at UBS Global Healthcare Conference 2025 Transcript

2025-11-10
Bio-Techne Corporation (TECH) UBS Global Healthcare Conference 2025 November 10, 2025 10:15 AM ESTCompany ParticipantsKim Kelderman - CEO, President &...

McDonald’s Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More.

2025-11-07
Targa Resources reported a solid third-quarter beat driven by volume growth in the gathering & processing segment and also plans to come in at the high end of the previous fiscal-2025 adjusted Ebitda guidance. It also bought back about $156 million of stock during the quarter and announced a 25% dividend increase for 2026; we thus expect investors to view this update positively. Bio-Techne reported below-expected financial results for its first-quarter 2026 (September), including revenue of $286.6 million, down 1% year over year, and flat adjusted earnings of $0.42 versus $0.42 for first-quarter 2025.

Bio-Techne to Present at Upcoming Investor Conferences

2025-11-06
Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences:

Bio-Techne (TECH) Margin Drops to 6% on $164M Loss, Challenging Profit Recovery Narratives

2025-11-06
Bio-Techne (TECH) reported net profit margins of 6%, dropping from 14.5% the previous year, with earnings declining at an average annual rate of 6.8% over the last five years. The latest results were hit by a sizable one-off loss of $164.1 million, complicating year-over-year comparisons and weighing on recent profitability. Despite this, forecasts point to annual earnings growth of 12.5% and revenue growth of 8.1%, both trailing the broader US market. Shares trade at $59.94, well below an...